Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.

Grade Last Price % Change Price Change
C 16.08 0.06% 0.01
CPRX closed up 0.06 percent on Monday, March 18, 2024, on 83 percent of normal volume.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Doji - Bullish? Reversal 0.00%
Outside Day Range Expansion 0.00%
Doji - Bullish? Reversal 0.06%
Outside Day Range Expansion -0.68%
Wide Bands Range Expansion -0.68%
Gapped Up Strength -0.68%
Wide Bands Range Expansion -3.25%
Gapped Up Strength -3.25%
NR7 Range Contraction -0.74%
NR7-2 Range Contraction -0.74%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 11 hours ago
Outside Day about 11 hours ago
Rose Above 10 DMA about 11 hours ago
10 DMA Resistance about 12 hours ago
Up 1% about 12 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Medication Disorders Virotherapy Epilepsy Pharmaceutical Sciences Prescription Drugs Stage Specialty Pharmaceutical Myasthenia Pharmaceutical Partners Treatment Of Epilepsy Urological Diseases Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome

Is CPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.2
52 Week Low 11.09
Average Volume 1,555,012
200-Day Moving Average 13.77
50-Day Moving Average 14.78
20-Day Moving Average 15.53
10-Day Moving Average 16.23
Average True Range 0.65
RSI (14) 57.08
ADX 33.04
+DI 29.40
-DI 16.02
Chandelier Exit (Long, 3 ATRs) 15.55
Chandelier Exit (Short, 3 ATRs) 15.44
Upper Bollinger Bands 17.74
Lower Bollinger Band 13.31
Percent B (%b) 0.62
BandWidth 28.55
MACD Line 0.51
MACD Signal Line 0.50
MACD Histogram 0.0114
Fundamentals Value
Market Cap 1.91 Billion
Num Shares 119 Million
EPS 0.55
Price-to-Earnings (P/E) Ratio 29.24
Price-to-Sales 4.66
Price-to-Book 4.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.03
Resistance 3 (R3) 17.03 16.71 16.87
Resistance 2 (R2) 16.71 16.46 16.71 16.82
Resistance 1 (R1) 16.39 16.31 16.55 16.40 16.77
Pivot Point 16.07 16.07 16.15 16.07 16.07
Support 1 (S1) 15.76 15.83 15.92 15.76 15.39
Support 2 (S2) 15.44 15.68 15.44 15.34
Support 3 (S3) 15.12 15.44 15.29
Support 4 (S4) 15.13